Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab.
Alexa M G A LaheijNiels W C J van de DonkPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)
Studying taste changes in patients treated with talquetamab following up on the described leads provides a new and unique opportunity to further unravel the pathophysiology of taste changes after cancer treatment.
Keyphrases